“Dawn’s extensive industry knowledge will play a key role in ensuring that we maintain a forward momentum in our commitment to developing and commercializing advanced biomaterial technology platforms,” said Jeff Robertson, president. “Her leadership will help us continue to build a strong R&D pipeline while also maintaining our focus on business partnerships with clients and academia.”
Eringis has also held positions at Pfizer, Inc., Johnson & Johnson-Merck, Guilford Pharmaceuticals, Inc., the American Red Cross and Locus Pharmaceuticals, Inc. She holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and a Masters in Business Administration from The Wharton School.
About Secant Medical: Secant Medical provides advanced biomaterials and biomedical textile structures to the medical device industry. We partner with clients to design, develop, and manufacture high-performance biomedical structures for applications in cardiovascular, neurovascular, orthopedic and general surgery. Built on a 70-year history, we’re committed to the future of regenerative medicine and actively engage in research partnerships to advance next-generation biomaterial technology into practical applications for the medical device and pharmaceutical industries. Secant Medical is a business unit of Fenner PLC, a worldwide leader in reinforced polymer engineering headquartered in Yorkshire, England. For more information, contact Maria Fontanazza at 215-257-8680 x2192 or email@example.com; or visit www.secantmedical.com.